Therefore, coadministration of PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) with TMZ or procarbazine is anticipated to ameliorate tumor cytotoxicity in the presence of MGMT. This evidence concerns the gene PARP1 and neoplasm.